Study to Evaluate Safety, Drug Levels, Food and Relative Bioavailability of BMS-986365 in Healthy Adult Male Participants

A Phase 1, Two-part, Open-label Single Ascending Dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of BMS-986365, Food and Proton Pump Inhibitor Effects, and Relative Bioavailability of BMS-986365 Capsule Compared to Tablet Formulation in Healthy Adult Male Participants

The purpose of this study is to evaluate the safety, tolerability, drug levels, food effects and relative bioavailability of BMS-986365 in healthy male participants.

Inclusion Criteria:

• Healthy adult male participants as determined by no clinically significant deviations from normal in medical history, physical examination, vital signs, ECGs, echocardiogram, or clinical laboratory assessments as determined by the investigator.
• Body mass index (BMI) of 18.0 to 32.0 kg/m^2, inclusive.

Exclusion Criteria:

• Any significant acute or chronic illness.
• Prior history of heart failure, ischemic heart diseases, serious cardiac arrythmias, or prolonged QT interval.
• History of allergy/hypersensitivity to any component (including excipients) of BMS-986365 study interventions or related compounds.
• Other protocol-defined inclusion/exclusion criteria apply.